Shares of Geron (NASDAQ: GERN) are up 6.75% after the company this morning said its telomerase inhibitor, imetelstat, has been granted Fast Track designation by the United States Food and Drug Administration (FDA) to treat adults with transfusion-dependent anemia due to Low or Intermediate-1 risk myelodysplastic syndromes (MDS) who are non-del and who are refractory or resistant to treatment with an erythropoiesis stimulating agent. Geron initially developed imetelstat, which is exclusively licensed to Janssen Biotech, Inc. worldwide. Janssen sponsored the application for Fast Track designation using preliminary data from IMerge, the ongoing clinical trial being conducted by Janssen in lower risk MDS. The expanded part 1 of the IMerge trial is currently open for patient enrollment.
To view the full press release, visit: http://nnw.fm/O4nxD
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information, visit the company’s website at www.geron.com.
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information please visit https://www.NetworkNewsWire.com